11 novembre 2020 – Walder Wyss advised the investors co-led by Kurma Partners and Sunstone Life Science Ventures on the CHF 20m series A financing of Synendos Therapeutics AG.

Synendos Therapeutics AG is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders.

The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).